medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2009, Número 09-10

<< Anterior Siguiente >>

Medicina & Laboratorio 2009; 15 (09-10)


Síndrome de Cushing

Gutiérrez RJ, Latorre SG, Campuzano MG

Idioma: Español
Referencias bibliográficas: 56
Paginas: 411-430
Archivo PDF: 816.28 Kb.


RESUMEN

El síndrome de Cushing se presenta como resultado de la exposición a altas concentraciones de cortisol. A pesar de que se considera una enfermedad rara, se caracteriza por una alta morbilidad y mortalidad, si no se trata; por lo tanto, el diagnóstico temprano y la identificación de su causa son indispensables para un manejo adecuado del paciente. El diagnóstico de síndrome de Cushing es un desafío para el endocrinólogo, quien debe conocer la utilidad y la correcta interpretación de las pruebas diagnósticas. El diagnóstico incluye dos pasos: primero, confirmar el estado de hipercortisolemia con la ayuda de varias pruebas de tamización; y segundo, identificar la causa de la hipercortisolemia. Los resultados de laboratorio deben ser interpretados en forma conjunta con las manifestaciones clínicas y con los hallazgos radiológicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50.

  2. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s syndrome. Endocrinol Metab Clin North Am 2008; 37: 135-149, ix.

  3. Orth DN. Cushing’s syndrome. N Engl J Med 1995; 332: 791-803.

  4. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006; 367: 1605-1617.

  5. Lahera Vargas M, da Costa CV. Prevalence, etiology and clinical findings of Cushing’s syndrome. Endocrinol Nutr 2009; 56: 32-39.

  6. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing’s syndrome: a population- based study. J Clin Endocrinol Metab 2001; 86: 117-123.

  7. Hutter AM, Jr., Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966; 41: 572-580.

  8. Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab 2009; 94: 3121-3131.

  9. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC, et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing’s disease. J Clin Endocrinol Metab 1995; 80: 2791-2794.

  10. Koch CA, Doppman JL, Watson JC, Patronas NJ, Nieman LK. Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome. N Engl J Med 1999; 341: 1399-1400.

  11. Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become “supersensitive” to melanocortin peptides. Mol Cell Endocrinol 1994; 102: R7-11.

  12. Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 1994; 23: 641-654.

  13. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-364.

  14. Tauchmanova L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006; 91: 1779-1784.

  15. Teves DA. Clinical approach of cushing syndrome resulting from ACTH-producing metastatic neuroendocrine tumor. The Endocrinologist 2005; 15: 401- 404.

  16. Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, et al. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 3745-3751.

  17. Newell-Price J, Grossman A. Diagnosis and management of Cushing’s syndrome. Lancet 1999; 353: 2087-2088.

  18. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540.

  19. Kola B, Grossman AB. Dynamic testing in Cushing’s syndrome. Pituitary 2008; 11: 155- 162.

  20. Santos S, Santos E, Gaztambide S, Salvador J. [Diagnosis and differential diagnosis of Cushing’s syndrome]. Endocrinol Nutr 2009; 56: 71-84.

  21. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93: 1553-1562.

  22. Stewart PM. Classification and pathophysiology of Cushing’s syndrome. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Kronenberg: Williams Textbook of Endocrinology, 11th ed. Philadelphia; WB Saunders. 2008.

  23. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602.

  24. Nieman LK, Ilias I. Evaluation and treatment of Cushing’s syndrome. Am J Med 2005; 118: 1340- 1346.

  25. Castro M, Moreira AC. Screening and diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metabol 2007; 51: 1191-1198.

  26. Makras P, Toloumis G, Papadogias D, Kaltsas GA, Besser M. The diagnosis and differential diagnosis of endogenous Cushing’s syndrome. Hormones (Athens) 2006; 5: 231-250.

  27. Cizza G, Nieman LK, Doppman JL, Passaro MD, Czerwiec FS, Chrousos GP, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81: 3573-3577.

  28. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome- -recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997; 34 ( Pt 3): 222-229.

  29. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxf); 43: 545-550.

  30. Findling JW, Raff H. Screening and diagnosis of Cushing’s syndrome. Endocrinol Metab Clin North Am 2005; 34: 385-402, ix-x.

  31. Reimondo G, Allasino B, Bovio S, Paccotti P, Angeli A, Terzolo M. Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing’s syndrome. Eur J Endocrinol 2005; 153: 803-809.

  32. Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 1998; 83: 2681-2686.

  33. Erickson D, Natt N, Nippoldt T, Young WF, Jr., Carpenter PC, Petterson T, et al. Dexamethasonesuppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. J Clin Endocrinol Metab 2007; 92: 2972-2976.

  34. Morris DG, Grossman AB. Dynamic tests in the diagnosis and differential diagnosis of Cushing’s syndrome. J Endocrinol Invest 2003; 26: 64-73.

  35. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998; 19: 647-672.

  36. Dichek HL, Nieman LK, Oldfield EH, Pass HI, Malley JD, Cutler GB, Jr. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin- dependent Cushing’s syndrome. J Clin Endocrinol Metab 1994; 78: 418-422.

  37. Yanovski JA, Cutler GB, Jr., Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. JAMA 1993; 269: 2232-2238.

  38. Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropindependent Cushing’s syndrome. J Clin Endocrinol Metab 1997; 82: 1780-1785.

  39. Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 2003; 88: 5299-5306.

  40. Newell-Price J, Morris DG, Drake WM, Korbonits M, Monson JP, Besser GM, et al. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 2002; 87: 1640-1645.

  41. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic- Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84: 440-448.

  42. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 2003; 138: 980-991.

  43. Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999; 84: 2489-2495.

  44. Lindsay JR, Nieman LK. Differential diagnosis and imaging in Cushing’s syndrome. Endocrinol Metab Clin North Am 2005; 34: 403-421, x.

  45. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120: 817-820.

  46. Choyke PL. Commentary on “computed tomography in the diagnosis of adrenal disease” and “nonfunctioning adrenal masses: incidental discovery on computed tomography”. AJR Am J Roentgenol 2009; 192: 568-570.

  47. Honigschnabl S, Gallo S, Niederle B, Prager G, Kaserer K, Lechner G, et al. How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. Eur J Radiol 2002; 41: 113-122.

  48. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25: 309-340.

  49. Sohaib SA, Rockall AG, Reznek RH. Imaging functional adrenal disorders. Best Pract Res Clin Endocrinol Metab 2005; 19: 293-310.

  50. Kurtaran A, Traub T, Shapiro B. Scintigraphic imaging of the adrenal glands. Eur J Radiol 2002; 41: 123-130.

  51. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med 2006; 36: 212- 227.

  52. Gross MD, Avram A, Fig LM, Rubello D. Contemporary adrenal scintigraphy. Eur J Nucl Med Mol Imaging 2007; 34: 547-557.

  53. Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84: 487-492.

  54. Colao A, Faggiano A, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G. Inferior petrosal sinus sampling in the differential diagnosis of Cushing’s syndrome: results of an Italian multicenter study. Eur J Endocrinol 2001; 144: 499-507.

  55. Utz A, Biller BM. The role of bilateral inferior petrosal sinus sampling in the diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metabol 2007; 51: 1329-1338.

  56. Ilias I, Chang R, Pacak K, Oldfield EH, Wesley R, Doppman J, et al. Jugular venous sampling: an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormonedependent Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 3795-3800.




2020     |     www.medigraphic.com